Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, pharmacokinetic and pharmacodynamic profiles of single ascending doses of tolvaptan in patients with autosomal dominat polycystic kidney disease with preserved renal function (Trial 248)

Next Previous
X
Search
Trial Profile

Safety, pharmacokinetic and pharmacodynamic profiles of single ascending doses of tolvaptan in patients with autosomal dominat polycystic kidney disease with preserved renal function (Trial 248)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tolvaptan (Primary)
  • Indications Autosomal dominant polycystic kidney disease
  • Focus Pharmacodynamics; Pharmacokinetics

    • Most Recent Events

    • 27 Feb 2017 New trial record
    • 20 Feb 2017 Results of three phase II studies published in the Journal of Clinical Pharmacology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top